At a glance
ClinicalIndex Comparison RecordN/ACompleted· 46 enrolled
Drug / intervention
IL-2drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases (Systemic Lupus Erythematosus, Primary Sjögren Syndrome, Juvenile Idiopathic Arthritis)
In Brief
A clinical study evaluating IL-2 for Systemic Lupus Erythematosus. Completed, enrolled 46 participants across 1 site.
Detailed Summary
The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children with rheumatic diseases (Systemic Lupus Erythematosus, Primary Sjögren Syndrome, Juvenile Idiopathic Arthritis).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Lupus Erythematosus
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartAug 2020
Primary CompletionMay 2022
Study CompletionJun 2022
TodayJul 2026
First PostedMay 21, 2020
Enrollment StartAug 15, 2020
Primary CompletionMay 31, 2022
Study CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.1 years ago
Interventions
IL-2drug
Patients were received low dose recombinant human Interleukin-2